Global Information
회사소개 | 문의 | 비교리스트

반려동물 백신 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Companion Animal Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 995771
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 4,750 ₩ 6,306,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 6,970,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,630,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,617,000 PDF & Excel (Corporate License)


반려동물 백신 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Companion Animal Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 반려동물 백신 시장 규모는 2020년에 약 27억 6,800만 달러를 기록했습니다.

시장은 예측기간 중 5.6%의 CAGR로 확대되고, 2026년에는 38억 5,100만 달러 매출이 전망됩니다.

시장에 대한 COVID-19 팬데믹의 영향은 중대하다고 예상됩니다. COVID-19 팬데믹 동안 반려동물 치료에 관한 수의 전문가에 대한 특정 예방적 가이드라인이 2020년 7월에 질병관리예방센터에 의해 제시되었습니다. 또한 질병관리예방센터 등 많은 정부당국은 동물 병원 및 진료소에 긴급 및 구급 방문이나 시술을 우선하도록 제안했습니다. 국가의 기관에 의한 이러한 대처는 동물 의료 관리에서 진단 기기의 의존과 사용을 줄일 것으로 보입니다. 또한 OIE : 세계동물보건기구에 의하면 세계의 의료 시설과 COVID-19 검사기관 부족을 극복하기 위해서 대부분의 수의 연구소가 인간의 COVID-19 검사에 적극적으로 관여하고 있습니다. 그러나 일부 병원이나 진료소에서는 이 팬데믹 상황에서 바이러스가 감염되지 않도록 명확한 대책을 강구하고 있습니다. 예를 들어 Prestige Animal Hospitals는 동물 치료에서 예방 조치를 강구하고 있습니다. 그들은 또한 주인이 진단 또는 치료를 위해 동물을 하차시킬 수 있는 "Drop Off 검사" 프로그램을 도입했습니다. 결과와 치료 계획은 전화/메일로 주고 받게 됩니다. 따라서 주로 COVID-19의 발생시 수의 진찰이 감소했기 때문에 반려동물 백신 시장에 약간의 단기적인 악영향이 나타납니다.

세계의 반려동물 백신 시장 성장은 주로 개나 고양이 등의 반려동물 증가와 인수 공통 감염증 증례 증가에 의해 추진되고 있습니다. 현재 주로 기르는 반려동물은 개, 고양이, 말 등입니다. 시장은 특히 개와 고양이 때문에, 인간으로부터 동물로의 헬스케어 부문의 약물 크로스오버를 점점 더 채용하고 있습니다. 최근 애완동물 소유수가 크게 증가하고 있습니다.

세계의 반려동물 백신(Companion Animal Vaccine) 시장에 대해 조사했으며, 시장 개요와 함께 기술별, 동물 종별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 추진력
    • 개나 고양이 등의 반려동물 증가
    • 인수 공통 감염증 증례 증가
  • 시장 성장 억제요인
    • 백신 개발의 고비용과 규제상 우려
  • Porter's Five Force 분석

제5장 시장 세분화

  • 기술별
    • 약독화 생백신
    • 불활화 백신
    • 톡소이드 백신
    • 재조합 백신
    • 기타
  • 동물 종별
    • 고양이
    • 기타 동물
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim GmbH
    • Brilliant Bio Pharma
    • Merck & Co. Inc.
    • Virbac
    • Zoetis Inc.
    • Indian Immunologicals Ltd
    • Bioveta AS
    • Vetoquinol SA
    • Merial(Sanofi)

제7장 시장 기회와 동향

KSM 21.03.22

The companion animal vaccine market was valued at approximately USD 2,768 million in 2020, and it is expected to witness a revenue of USD 3,851 million in 2026, with a CAGR of 5.6% over the forecast period.

The impact of the COVID-19 pandemic on the market is expected to be significant. Certain specific and precautionary guidelines were given to veterinary professionals to treat companion animals during the COVID-19 pandemic by the Centers for Disease Control and Prevention in July 2020. Additionally, many government authorities, such as the Centers for Disease Control and Prevention, recommended veterinary hospitals and clinics to prioritize urgent and emergency visits and procedures. This initiative by such national bodies may reduce the dependence on and usage of diagnostic equipment in veterinary healthcare management. Moreover, according to the OIE (World Organization for Animal Health), most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the shortage of healthcare facilities and COVID-19 testing laboratories, globally. However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. For instance, Prestige Animal Hospitals has been taking precautionary measures in the treatment of animals. It also introduced a 'Drop Off Exams' program that allows the owner to drop off the animal for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. Hence, a slight short-term negative impact is witnessed on the companion animal vaccine market, primarily due to the reduced veterinary visits during the COVID-19 outbreak.

The growth of the global companion animal vaccines market is primarily driven by the rising adoption of companion animals, such as dogs and cats, and the increasing cases of zoonotic diseases. At present, companion animals are among the major domesticated animals, and this category is dominated by dogs, cats, and horses. The market studied has been increasingly adopting drug crossovers from the human healthcare sector to the animal healthcare sector, especially dogs and cats. The recent years have observed a significant rise in the number of pet ownership.

According to the annual report of the European Pet Food Industry Association (FEDIAF) in 2020, dogs and cats were found to be the major pets adopted in Europe. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to increase during the forecast period.

In the past few years, considering the risk of transferring human diseases to animals and vice versa, the market studied observed increased demand for vaccines for companion animals. New product launches based on emerging technologies, collaborations, mergers and acquisitions, and regional expansions are key strategic initiatives undertaken by these industry players. For instance, in October 2019, Zoetis launched Versican Plus Bb Oral, the first oral vaccine for dogs in Europe, for protection against Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC). Thus, due to the development of innovative solutions, the market studied is expected to record significant growth rates.

Key Market Trends

The Live Attenuated Vaccines Segment is Expected to Hold a Major Share over the Forecast Period

Live attenuated vaccines contain a weakened version of the living microbe, making it ineffective to cause diseases. They produce a similar, yet weakened reaction, as compared to that of natural infections. Effective cellular and antibody responses are established by the immune system with single or multiple doses of a vaccination, which aids in providing long-term immunity against infectious pathogens. The live attenuated vaccines are kept refrigerated to sustain their potency. Besides, if the vaccine needs to be shipped overseas or stored by healthcare workers, especially in developing countries that lack widespread refrigeration, a live vaccine may not be the best choice.

Mostly, vaccines licensed for oral or intranasal administration are attenuated. These vaccines must be stored and handled properly, and strict attention must be paid to temperature, even in the lyophilized (free-dried) state. After the reconstitution, the vaccine's dose should be administered promptly (within one hour) or discarded.

Moreover, the development and launch of new vaccines and a robust pipeline are expected to boost the market growth. For instance, in December 2019, Merck Animal Health launched two new vaccines, namely the Nobivac EDGE DAPPV + L4, a combo vaccine to include parainfluenza protection, and the Nobivac EDGE DAPPV combo vaccine to include parainfluenza protection in dogs. Hence, these vaccines are expected to account for the largest market share during the forecast period.

The North American Companion Animal Vaccine Market is Anticipated to Grow Tremendously over the Forecast Period

The major factors driving the North American companion animal vaccine market include the increasing adoption of companion animals, the surging prevalence of diseases, such as zoonosis, the availability of advanced veterinary healthcare infrastructure, and the presence of key market players, leading to the development of companion vaccines.

The growing pet population, along with an increase in spending on pet care, is fueling the market growth. For instance, according to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 85 million families or 67% of US households owned a pet, up from 56% of US households in 1988. Additionally, during 2019-2020, around 63.4 million US households owned a dog.

Moreover, as per the American Pet Products Association, in 2020, it was estimated that around USD 99.0 billion was spent on pets in the United States, up from USD 95.7 billion in 2019. Furthermore, the Centers for Disease Control and Prevention (CDC), the Department of the Interior (DOI) and the US Department of Agriculture (USDA) released a 2019 report, listing the zoonotic diseases of the highest concern in the United States. This factor may boost the market growth, as it may increase the demand for vaccines to eradicate infectious diseases in companion animals.

To increase their market shares, market players are adopting various strategies, such as product launches, product developments, collaborations, mergers, acquisitions, and expansions. For instance, in October 2020, Elanco signed an agreement with Bayer's Animal Health Business to acquire its Animal Health business in a transaction valued at USD 7.6 billion. Thus, the rising incidence rates of infectious diseases in companion animals, along with increasing product launches, may show significant market growth over the forecast period.

Competitive Landscape

The companion animal vaccine market is moderately consolidated. In terms of market share, major players, such as Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Merck & Co. Inc., Zoetis Inc., and Bioveta AS, among others, hold the largest market shares. Key players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand the global product portfolios and secure their positions in the global market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of Companion Animals, such as Dogs and Cats
    • 4.2.2 Increasing Cases of Zoonotic Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Vaccine Development and Regulatory Concern
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Live Attenuated Vaccines
    • 5.1.2 Inactivated Vaccines
    • 5.1.3 Toxoid Vaccines
    • 5.1.4 Recombinant Vaccines
    • 5.1.5 Other Technologies
  • 5.2 By Animal Type
    • 5.2.1 Dogs
    • 5.2.2 Cats
    • 5.2.3 Other Animal Types
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES
    • 6.1.1 Elanco Animal Health Incorporated
    • 6.1.2 Boehringer Ingelheim GmbH
    • 6.1.3 Brilliant Bio Pharma
    • 6.1.4 Merck & Co. Inc.
    • 6.1.5 Virbac
    • 6.1.6 Zoetis Inc.
    • 6.1.7 Indian Immunologicals Ltd
    • 6.1.8 Bioveta AS
    • 6.1.9 Vetoquinol SA
    • 6.1.10 Merial (Sanofi)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q